DBV Technologies S.A. (DBVT)

Compare

6.50

-1.36

(-17.30%)

At close: April 4 at 4:00:02 PM EDT

6.50

0.00

(0.00%)

After hours: April 4 at 4:55:47 PM EDT

Novo gains Lexicon obesity drug; CRISPR COO to step down

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off 57% of its workforce and Bicycle Therapeutics shook up its leadership team.

BioPharma Dive 9 days ago

CRSP

DBV.PA

NVO
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrantsDBV sufficiently funded through the expected Biologics License Application (BLA) submission to Food and Drug Administration (FDA)

GlobeNewswire 10 days ago

DBVT
-17.30%
DBVTF
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results1 COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required FDA confirms safety exposure data generated from VITESSE Phase 3 clinical study and VITESSE Open-Labe

GlobeNewswire 13 days ago

DBVT
-17.30%
DBVTF
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer,

GlobeNewswire last month

DBVT
-17.30%
DBVTF
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: 266,868 DBV Tec

GlobeNewswire 2 months ago

DBVT
-17.30%
DBVTF
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adv

GlobeNewswire 2 months ago

DBVT
-17.30%
DBVTF
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated Approval pathway for the therapy, offering a streamlined regulatory process for peanut allergy treatment. The FDA confirmed that the Viaskin Peanut patch satisfies the key criteria for Accelerated Approval, including addressing a serious condition and offering a meaningful advantage over existing ther

Benzinga 3 months ago

DBVT
-17.30%
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteri

GlobeNewswire 3 months ago

DBVT
-17.30%
DBVTF
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2024102,847,501Total gross of voting rights: 102,847,501Total net* of voting rights: 102,582,335 * Net total = total number of voting rights attached to shares – shares without v

GlobeNewswire 4 months ago

DBVT
-17.30%
DBVTF
DBV Technologies Announces Plan to Implement ADS Ratio Change

Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value

GlobeNewswire 4 months ago

DBVT
-17.30%
DBVTF
DBV Technologies’ stock slides as financial woes worsens

The company reported that it does not have sufficient cash reserves to operate for the next 12 months and can only fund operations into Q1 2025.

Pharmaceutical Technology 4 months ago

DBV.PA
DBV Technologies Reports Third Quarter 2024 Financial Results

Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024

GlobeNewswire 4 months ago

DBVT
-17.30%
DBVTF
DBV Technologies price target raised to $7 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on DBV Technologies (DBVT) to $7 from $5 and keeps a Buy rating on the shares after DBV reached an agreement with the FDA regarding the regulatory pathway for the Viaskin Peanut patch in toddlers aged one to three under the Accelerated Approval pathway. The firm believes the recent regulatory updates for the peanut patch brings “long-awaited clarity” and addresses one of the “significant regulatory overhangs for its advancement toward potential appr

TipRanks 5 months ago

DBVT
-17.30%
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results

GlobeNewswire 5 months ago

DBVT
-17.30%
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, October 24 – 28th, 2024 in Boston, Massachusetts. This year’s meeting will feature a “Product Theater” on What Defines an Optimal Peanut Allerg

GlobeNewswire 5 months ago

DBVT
-17.30%
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 09/30/2024 96,501,526 Total gross of voting rights: 96,501,526 Total net* of voting rights: 96,199,467 * Net total = total number of voting rights attached to shares – shares without

GlobeNewswire 5 months ago

DBVT
-17.30%
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin® Peanut Patch in peanut allergic children ages 4 – 7 years oldTopline results of VITESSE data are expected by Q4 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa

GlobeNewswire 6 months ago

DBVT
-17.30%
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 3:00 pm ET, in New York City. A live webcast of

GlobeNewswire 6 months ago

DBVT
-17.30%
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights07/31/2024 96,498,927 Total gross of voting rights: 96,498,927 Total net* of voting rights: 96,214,457 * Net total = total number of voting rights attached to shares – shares without votin

GlobeNewswire 7 months ago

DBVT
-17.30%
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2024, of its Half-Year Report with t

GlobeNewswire 8 months ago

DBVT
-17.30%

Performance Overview

Return	DBVT	CAC 40 (^FCHI)
YTD	+106.48%	-1.43%
1-Year	+333.33%	-10.75%
3-Year	+104.40%	+8.08%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

DBV Technologies S.A. (DBVT)

Novo gains Lexicon obesity drug; CRISPR COO to step down

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies’ stock slides as financial woes worsens

DBV Technologies Reports Third Quarter 2024 Financial Results

DBV Technologies price target raised to $7 from $5 at H.C. Wainwright

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

Performance Overview